France: ANSM Mails Desogestrel Meningioma Risk Letters to Patients

On September 10, 2026, France's Agence nationale de sécurité du médicament et des produits de santé (ANSM) began mailing personalized information letters to women using desogestrel-based contraceptives, notifying them of a very low risk of meningioma associated with prolonged use. Prescribers received a parallel letter alerting them that their patients would be contacted. The mailing operationalizes the July 2026 European Medicines Agency (EMA) recommendation to add meningioma to the Summary of Product Characteristics (SmPC) and patient leaflet, and follows the August 2026 Direct Healthcare Professional Communication.

The campaign is the latest step in a signal ANSM has tracked since the EPI-PHARE study, which found a very small increase in meningioma incidence in women using desogestrel for at least one year. For marketing authorisation holders (MAHs) of the affected products, the patient mailing now triggers a predictable wave of inbound medical-information queries and switch requests over the coming weeks.

Which products and marketing authorisation holders are affected?

The letters cover the full desogestrel and etonogestrel contraceptive range sold in France. Desogestrel-only pills include Antigone 75 micrograms, Cerazette 0.075 mg, Elfasette 75 micrograms, Optimizette 75 micrograms, and the Biogaran, Cristers and Sandoz desogestrel 75 microgram generics. Combined ethinylestradiol pills cover Desobel 150/20 and 150/30, Mercilon, Varnoline and Varnoline continu, plus Biogaran, EG and Viatris desogestrel/ethinylestradiol 150/20 and 150/30 generics. The Nexplanon 68 mg implant and the Nuvaring, Etoring and Etonogestrel/ethinylestradiol Viatris vaginal rings are also in scope. Organon (Cerazette, Mercilon, Nuvaring, Nexplanon), Viatris, Sandoz, Biogaran, EG Labo and Cristers are the MAHs whose pharmacovigilance, medical-information and regulatory-affairs teams must act now.

What is the magnitude of the risk, and who is most exposed?

ANSM estimates one additional meningioma case per 67,000 women using these medicines. The risk rises for women over 45 or exposed for more than five years. A prior exposure to a progestin already flagged for meningioma risk, cyproterone acetate, nomegestrol or chlormadinone, makes the risk significant from the first year of desogestrel 75 microgram use. One year after stopping treatment, the excess risk is no longer observed. Meningioma is most often a non-cancerous tumor of the meninges, and the large majority of desogestrel users will never develop one. The patient letter states explicitly that receiving it does not mean a meningioma has been diagnosed or suspected.

What must pharmacovigilance and regulatory affairs teams do now?

The patient mailing makes the signal visible to end users directly, so MAH teams should pre-position their response. Update inbound medical-information scripts to mirror the ANSM letter wording, including the reassurance that no urgent consultation is needed in the absence of symptoms and that contraception should not be stopped without medical advice. Brief call-center and field teams on the switch-demand scenario, since a share of patients will ask about alternative methods. Confirm that risk-management plans and PSURs already reflect the EMA's July 2026 SmPC and leaflet update, and route any adverse-event reports triggered by the letters through standard pharmacovigilance intake. Cross-check that patient-facing materials, package leaflets and the company website stay consistent with the ANSM and EMA messaging.

What should patients and prescribers do?

ANSM advises women to raise the letter at their next routine contraception review with their doctor or midwife, not to seek urgent care in the absence of symptoms. Contraception should be reassessed annually, factoring in age, duration of desogestrel use, prior progestin exposure and individual health. Women should not stop their contraception on their own initiative, as abrupt cessation carries a risk of unintended pregnancy. The prescriber letter asks clinicians to expect these consultations. Persistent headaches, vision, speech or balance disturbances, muscle weakness, memory problems or new or worsening epilepsy warrant a medical consultation. ANSM has opened a user desk and an information page to answer patient questions.

Continuous, per-jurisdiction real-time monitoring surfaces this kind of safety-communication drop the moment a supervisor publishes it, before the patient letters even reach the mailbox.

Subscribe to the free newsletter

For affected MAH teams, the immediate checklist is narrow: align medical-information scripts with the ANSM letter, confirm the SmPC and leaflet already carry the EMA's July 2026 meningioma wording, and stand ready for the inbound query wave as letters land. Clinicians should plan a brief, reassuring consultation at the next routine visit, and patients should not discontinue contraception before that conversation.